SG10201804000TA - Compositions for the treatment of rheumatoid arthritis and methods of using same - Google Patents

Compositions for the treatment of rheumatoid arthritis and methods of using same

Info

Publication number
SG10201804000TA
SG10201804000TA SG10201804000TA SG10201804000TA SG10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA
Authority
SG
Singapore
Prior art keywords
methods
rheumatoid arthritis
compositions
treatment
same
Prior art date
Application number
SG10201804000TA
Other languages
English (en)
Inventor
Xiaohong Huang
Martine Jasson
Vanessa Marks
Allen Radin
Chungpeng Fan
Hoogstraten Hubert Van
Stefano Fiore
Adelsberg Janet Van
Mark Genovese
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of SG10201804000TA publication Critical patent/SG10201804000TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201804000TA 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same SG10201804000TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US201462008787P 2014-06-06 2014-06-06
EP14306366 2014-09-05

Publications (1)

Publication Number Publication Date
SG10201804000TA true SG10201804000TA (en) 2018-07-30

Family

ID=51518724

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201804000TA SG10201804000TA (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Country Status (11)

Country Link
US (1) US20160280782A1 (ja)
EP (2) EP3071230B1 (ja)
JP (3) JP6657089B2 (ja)
KR (3) KR20220056254A (ja)
CN (1) CN106413748A (ja)
AU (2) AU2014352801B2 (ja)
CA (1) CA2930615C (ja)
MX (2) MX2016006595A (ja)
PL (1) PL3071230T3 (ja)
SG (1) SG10201804000TA (ja)
WO (1) WO2015077582A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
AU2016348418B8 (en) 2015-11-03 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
CA3016880A1 (en) * 2016-03-07 2017-09-14 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
CA3084757A1 (en) 2017-12-07 2019-06-13 Fujimori Kogyo Co., Ltd. Port-equipped bag and cap-equipped bag
US11319375B2 (en) * 2018-08-29 2022-05-03 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
CN114206442A (zh) 2019-01-31 2022-03-18 赛诺菲生物技术公司 用于治疗幼年特发性关节炎的抗il-6受体抗体
TW202106712A (zh) * 2019-04-24 2021-02-16 美商再生元醫藥公司 類風溼性關節炎之診斷及治療方法
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
ES2799439T3 (es) * 2013-11-22 2020-12-17 Sanofi Biotechnology Composiciones para el tratamiento de la artritis reumatoide y métodos de uso de las mismas

Also Published As

Publication number Publication date
EP3071230B1 (en) 2020-04-08
PL3071230T3 (pl) 2020-09-21
JP6657089B2 (ja) 2020-03-04
EP3071230A1 (en) 2016-09-28
AU2014352801B2 (en) 2020-05-28
CA2930615A1 (en) 2015-05-28
JP2024026223A (ja) 2024-02-28
AU2014352801A1 (en) 2016-06-23
MX2020011993A (es) 2021-01-29
WO2015077582A1 (en) 2015-05-28
JP2022033891A (ja) 2022-03-02
CA2930615C (en) 2023-04-04
CN106413748A (zh) 2017-02-15
AU2020223706B2 (en) 2024-04-18
KR20160079121A (ko) 2016-07-05
EP3770173A1 (en) 2021-01-27
US20160280782A1 (en) 2016-09-29
AU2020223706A1 (en) 2020-09-10
MX2016006595A (es) 2016-09-06
KR20230155586A (ko) 2023-11-10
JP2016539125A (ja) 2016-12-15
KR20220056254A (ko) 2022-05-04

Similar Documents

Publication Publication Date Title
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
MY191169A (en) Anti-fcrh5 antibodies
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2020002289A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
PH12015502788A1 (en) Antibody formulations and methods
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2015013901A (es) Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2021010472A (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
NZ715582A (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
MX2014013678A (es) Agentes para neutralizacion de influenza.
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2019014714A (es) Anticuerpos anti-trkb.
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.